Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NXP900

Small molecule · Inhibitor of SRC proto-oncogene, non-receptor tyrosine kinase (SRC) and YES proto-oncogene 1, Src family tyrosine kinase (YES1) · developed by Nuvectis Pharma

Phase 1 Most advanced trial
NVCT Developer
1 Registered trials

What is NXP900?

NXP900 is an orally administered inhibitor of SRC family kinases, including SRC and YES1. It binds these kinases and locks them in their closed conformation, inhibiting their kinase activity and their association with signaling partners. It is being studied in EGFR-mutated non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
SRC proto-oncogene, non-receptor tyrosine kinase (SRC), YES proto-oncogene 1, Src family tyrosine kinase (YES1)
Mechanism
Inhibitor of SRC proto-oncogene, non-receptor tyrosine kinase (SRC) and YES proto-oncogene 1, Src family tyrosine kinase (YES1)
Pathways
SRC family kinase signaling, tumor cell proliferation, metastasis
Therapy area
Oncology
Developer
Nuvectis Pharma, Inc. (NVCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07315113 Phase 1 EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting NVCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

EGFR Mutated Non-small Cell Lung Cancer PatientsEGFR Mutation Positive Non-small Cell Lung Cancer

More from Nuvectis Pharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVCT page.

Follow NVCT, the company behind NXP900

See NVCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.